Results 91 to 100 of about 5,946,067 (288)

Lifestyle Management in Menopause: A Systematic Review of Women With Premature Ovarian Insufficiency

Clinical Endocrinology, EarlyView.
ABSTRACT Objective Premature ovarian insufficiency (POI), the loss of ovarian function before age 40, increases the risk of cardiovascular disease, low bone mineral density, dementia and psychological distress. Lifestyle interventions reduce chronic disease risk in other populations and, with hormone therapy, may improve health outcomes in POI.
Ladan Yeganeh, Nathalie Vermeulen, Carolyn Ee, Helena Teede, Amanda J. Vincent   +4 more
wiley   +1 more source

Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events [PDF]

, 2015
Background In a phase III trial in patients with castration-resistant prostate cancer (CRPC) and bone metastases, denosumab was superior to zoledronic acid in reducing skeletal-related events (SREs; radiation to bone, pathologic fracture, surgery to ...
Balakumaran, A., Braun, A., Chi, K.N., Coleman, R.E., Fizazi, K., Klotz, L., Milecki, P., Ng, S., Pittman, K., Smith, M.R., Wang, H., Wei, R.   +11 more
core   +2 more sources

Associations of Semaglutide With Skeletal Outcomes in People With Obesity, With and Without Type 2 Diabetes: A Target Trial Emulation

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the associations between semaglutide initiation and long‐term skeletal outcomes in people with obesity, stratified by type 2 diabetes (T2D) status, using target trial emulation. Materials and Methods This retrospective cohort study used the TriNetX federated electronic health record network.
Yu‐Nan Huang, Min‐Yu Tsou, Pin‐Hung Li, Jo‐Ching Chen, Shao‐Chia Chen, Hao‐I Hsieh, Gideon Meyerowitz‐Katz, Yen‐Liang Liu, Pen‐Hua Su   +8 more
wiley   +1 more source

Osteonecrosis of the jaw during biyearly treatment with zoledronic acid for aromatase inhibitor associated bone loss in early breast cancer: A literature review

Journal of Bone Oncology, 2015
Osteonecrosis of the jaw (ONJ) is one of the most relevant and specific complication of biphosphonates. ONJ in patients receiving zoledronic acid every 3 to 4 weeks is frequently described, but the ONJ biyearly regimen used to reduce aromatase inhibitor ...
Hampig Raphael Kourie, Joelle Antoun, Elie El Rassy, Marc Rassy, Claude Sader-Ghorra, Joseph Kattan   +5 more
doaj   +1 more source

Alterations of bone proteins in medication‐related osteonecrosis of the jaw

European Journal of Oral Sciences, Volume 133, Issue 2, April 2025.
Abstract Changes in the protein expression pattern of osteoblastic lineage cells from the alveolar bone (OLAB) during medication‐related osteonecrosis of the jaw (MRONJ) have rarely been investigated. This lack of information is partly because of the limited availability of healthy samples and the lack of human alveolar bone cell lines for research ...
Andrea Schubert, Phillipp Brockmeyer, Philipp Kauffmann, Jan Wiegel, Florian Lautenbacher, Nicolai Miosge, Boris Schminke   +6 more
wiley   +1 more source

Bisphosphonate's and Intermittent Parathyroid Hormone's Effect on Human Spinal Fusion: A Systematic Review of the Literature. [PDF]

, 2017
There has been a conscious effort to address osteoporosis in the aging population. As bisphosphonate and intermittent parathyroid hormone (PTH) therapy become more widely prescribed to treat osteoporosis, it is important to understand their effects on ...
Acosta, Frank L, Hah, Raymond, Hsieh, Patrick C, Iorio, Justin A, Jakoi, Andre M, Liu, John C, Patel, Neil N, Pham, Martin H, Stone, Michael A, Wang, Jeffrey C   +9 more
core   +2 more sources

Radiographic Analysis of MRONJ in Osteoporotic and Oncologic Patients on Bisphosphonates or Denosumab

Oral Diseases, EarlyView.
ABSTRACT Introduction Medication‐Related Osteonecrosis of the Jaw (MRONJ) is a severe adverse effect of antiresorptive and antiangiogenic treatment, primarily in osteoporotic and oncologic patients. The disease is characterized by persistent jawbone necrosis that results in significant impairment of the quality of life of involved patients.
Omar Ghanaiem, Gavriel Chaushu, Daya Masri   +2 more
wiley   +1 more source

Study of Adverse Effect Profile of Parenteral Zoledronic Acid in Female Patients with Osteoporosis [PDF]

Journal of Clinical and Diagnostic Research, 2016
Introduction: Osteoporosis is still a under recognized entity in the population. Osteoporosis-related fractures can be prevented if people at risk can be screened, diagnosed and treated early.
Prem Kotian, Archith Boloor, Sushanth Sreenivasan   +2 more
doaj   +1 more source

Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid [PDF]

, 2011
Background To assess prognostic and predictive effects of clinical and biochemical factors in our published randomized study of a weekly low dose (metronomic arm) versus a conventional dosage of zoledronic acid (conventional arm) in breast cancer ...
Xinmin Zhao, Xiaofeng Xu, Qunling Zhang, Zhen Jia, Si Sun, Jian Zhang, Biyun Wang, Zhonghua Wang, Xichun Hu   +8 more
core   +1 more source

Combined Effects of Romosozumab and Zoledronate on the Development of Osteonecrosis of the Jaw

Oral Diseases, EarlyView.
ABSTRACT Objective This study aimed to assess the occurrence of medication‐related osteonecrosis of the jaw (MRONJ) in mice following the sequential administration of romosozumab and zoledronate and to confirm their inhibitory effects on osteoclast differentiation in vitro.
Hae‐Seo Park, Shihyun Kim, Seo‐Yeong An, Reuben H. Kim, Jongho Choi, Moon‐Young Kim   +5 more
wiley   +1 more source